1. Pink Sheet
  2. >>Geography

NICE OKs Sarclisa & Mayzent For Funding In England, But Rejects Vindaqel

Scottish HTA Body Greenlights Bavencio, Brineura

 
• By Ian Schofield

The health technology assessment bodies for England and Scotland have this week issued positive recommendations on the funding of several innovative new medicines on the National Health Service, including products for myeloma, kidney cancer and multiple sclerosis.

Close up of diverse young people show thumbs up recommending good quality service, multiethnic clients or customers
NICE and the SMC OKd funding for a range of new therapies this week • Source: Shutterstock

The health technology assessment body for England, the National Institute for Health and Care Excellence, has this week issued several positive recommendations for the funding of medicines on the National Health Service.

One of them is Sanofi’s Sarclisa (isatuximab), the first monoclonal antibody therapy to be approved for marketing in the EU in combination with pomalidomide and

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from United Kingdom

More from Europe